title: Will new drugs change the standard of care for patients with mantle cell lymphoma?
abstract: Mantle Cell lymphoma is a heterogeneous malignancy that has different subtypes with variable levels of aggressiveness. Research on the pathobiology of this disease is helping us understand the etiology for this heterogeneity and has the potential to guide future therapeutic options. The availability of the Ki67 proliferation index and the use of the MIPI score can help determine which of the numerous therapeutic options might be utilized. Minimal Residual Disease testing can act as a guide as to the potential benefit of maintenance therapy. This article discusses the current standard of care for Mantle Cell lymphoma and our current understanding of the pathobiology of the disease leading to strategies to improve patient outcomes with some of the newer targeted agents.
authors.affiliation: a Center for Lymphoid Malignancies , Columbia University Medical Center New York Presbyterian Hospital , New York , NY , USA.
authors.forename: Donald S
authors.initials: DS
authors.lastname: Colbourn
authors.affiliation: a Center for Lymphoid Malignancies , Columbia University Medical Center New York Presbyterian Hospital , New York , NY , USA.
authors.forename: Jennifer E
authors.initials: JE
authors.lastname: Amengual
authors.affiliation: a Center for Lymphoid Malignancies , Columbia University Medical Center New York Presbyterian Hospital , New York , NY , USA.
authors.forename: Changchun
authors.initials: C
authors.lastname: Deng
authors.affiliation: a Center for Lymphoid Malignancies , Columbia University Medical Center New York Presbyterian Hospital , New York , NY , USA.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Sawas
authors.affiliation: a Center for Lymphoid Malignancies , Columbia University Medical Center New York Presbyterian Hospital , New York , NY , USA.
authors.forename: Owen A
authors.initials: OA
authors.lastname: O'Connor
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000473:pathology; D058990:Molecular Targeted Therapy; D059039:Standard of Care
chemical_list: D000970:Antineoplastic Agents; D019394:Ki-67 Antigen
keywords: Ki67; MIPI; Mantle cell lymphoma; chemotherapy; gene expression profiling; immunotherapy; minimal residual disease; pathobiology; standard of care